<i>TP53</i> Combined Phenotype Score Is Associated with the Clinical Outcome of <i>TP53</i>-Mutated Myelodysplastic Syndromes

<i>TP53</i> Combined Phenotype Score Is Associated with the Clinical Outcome of <i>TP53</i>-Mutated Myelodysplastic Syndromes

Mutations of <i>TP53</i> are observed in 5–10% of patients in myelodysplastic syndrome (MDS) and are associated with adverse outcomes. Previous studies indicate that the <i>TP53</i> allelic state and variant allele frequency of <i>TP53</i> mutation impact patient...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Mariko Yabe, Aidana Z. Omarbekova, Meier Hsu, Hannah May, Maria E. Arcila, Ying Liu, Ahmet Dogan, Andrew M. Brunner, Valentina Nardi, Robert P. Hasserjian, Virginia M. Klimek
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
myelodysplastic syndromes
<i>TP53</i>
prognosis
overall survival
PHANTM combined phenotype score
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/1124622ac9fd44089ab464063b652144
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/1124622ac9fd44089ab464063b652144

Ejemplares similares